MedTrace Logo

Study of Intravenous Erenumab in Patients With Status Migrainosus

NCT04920331 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-02-22

No results posted yet for this study

Summary

The investigators will evaluate the efficacy for use of intravenous erenumab 140mg for treatment of status migrainosus in an open-label, pilot study.

Conditions

  • Status Migrainosus

Interventions

BIOLOGICAL

Erenumab

140mg single intravenous administration (60 minutes)

Sponsors & Collaborators

Principal Investigators

  • Juliana VanderPluym, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2022-02-04
Completion
2022-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920331 on ClinicalTrials.gov